Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh chemotherapy in favor of a more effective, targeted approach.

In the DESTINY-Breast09 trial, presented at this year's American Society of Clinical Oncology (ASCO) annual meeting, ...

Research presented at the ASCO Annual Meeting 2025 highlighted new potential standards of care and other advances in breast cancer.

The mainstay of treatment for human epidermal growth factor receptor (HER2)-positive breast cancer is chemotherapy with the monoclonal antibody trastuzumab with or without pertuzumab, administered ...

Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU ® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

Adding adjuvant pertuzumab to standard adjuvant chemotherapy and trastuzumab improved overall survival at 11 years of follow-up in patients with early human epidermal growth factor receptor 2 ...

TOKYO & BASKING RIDGE, N.J., June 02, 2025--(BUSINESS WIRE)--Positive results from the DESTINY-Breast09 phase 3 trial showed ENHERTU ® (trastuzumab deruxtecan) plus pertuzumab demonstrated a ...

AstraZeneca (NASDAQ:AZN) said on Monday that the late-stage trial for Enhertu, in combination with pertuzumab, showed significant improvement as a first line treatment of metastatic breast cancer ...